Sunitinib and capecitabine doses were escalated in serial patient cohorts.
在这些患者中舒尼替尼和卡培他滨的剂量逐步递增。
Conclusion Sunitinib inhibited bladder cell line T24 proliferation in dose-dependent and time dependent manner.
结论苹果酸舒尼替尼可呈浓度和时间依赖地抑制膀胱癌t 24细胞系增殖。
Conclusions: Sunitinib inhibited bladder cell line T24 proliferation in dose-dependent and time dependent manner.
结论：苹果酸舒尼替尼可呈浓度和时间依赖地抑制膀胱癌t 24细胞系增殖。
Objective To evaluate the efficacy and safety of sunitinib in the treatment of metastatic renal clear cell carcinoma in our single center.
目的评价单中心舒尼替尼治疗转移性肾脏透明细胞癌的疗效和安全性。
Cox proportional-hazards analysis of progression-free survival according to baseline characteristics favored sunitinib in all subgroups studied.
在研究的所有亚组中，根据基线特征进行的PFS的Cox风险比例分析均有利于舒尼替尼。
Cox proportional-hazards analysis of progression-free survival according to baseline characteristics favored sunitinib in all subgroups studied.
在研究的所有亚组中，根据基线特征进行的PFS的Cox风险比例分析均有利于舒尼替尼。
应用推荐